Research programme: cyclodextrin antiviral therapeutics - Cyclolab/Excivion/University of California
Latest Information Update: 28 Mar 2026
At a glance
- Originator Cyclolab; Excivion; University of California at Berkeley
- Class Antivirals; Cyclodextrins
- Mechanism of Action Viral nonstructural protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections; Dengue; Zika virus infection
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for preclinical development in Dengue in Hungary
- 28 Mar 2026 No recent reports of development identified for preclinical development in Dengue in United Kingdom
- 28 Mar 2026 No recent reports of development identified for preclinical development in Dengue in USA